(Q24198256)

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Safety and tolerability of zoster vaccine in adults ≥60 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of Tai Chi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Aging, immunity, and the varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Vaccination for preventing postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Disease burden of herpes zoster in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Preventing herpes zoster through vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Neurologic complications of the reactivation of varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Clinical practice. Herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Health state valuations from the general public using the visual analogue scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Family History as a Risk Factor for Herpes Zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Herpes zoster and quality of life: a self-limited disease with severe impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Herpes zoster: a common disease that can have a devastating impact on patients' quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Increasing incidence of herpes zoster among Veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Herpes zoster (shingles) and postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Q: Who should receive the shingles vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

What does epidemiology tell us about risk factors for herpes zoster?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

[Investigation methods in clinical cardiology. IV. Clinical measurements in cardiology: validity and errors of measurements]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

The treatment of varicella-zoster virus infection and its complications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008858.PUB2

7 January 2021

10.1002/14651858.CD008858.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23076951

1 reference

Consolidated OpenCitations Corpus – April 2017